‘Well-Established’ Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst
RBC Capital markets initiated coverage on Bausch + Lomb Corp (NYSE:BLCO) with an Outperform rating and a $22 price target. The analysts see…
Seagen’s Bladder Cancer Trial Data Meets Expectation, Analysts Say
Earlier today, Seagen Inc (NASDAQ:FBI) and Astellas Pharma Inc (OTC:ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev…
‘As of today, 1,092 people have tested positive for orthopoxvirus in NYC, which is presumed to be monkeypox.’ -NYC Healthy
https://twitter.com/nycHealthy/status/1551994547760234498
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
SomaLogic Acquires DNA Nanotechnology Provider For $35M
SomaLogic Inc (NASDAQ:SLGC) has agreed to acquire Palamedrix Inc for $14 million in cash and $21 million in SomaLogic common stock. Up…
Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development
Reneo Pharmaceuticals Inc (NASDAQ:RPHM) has reported results from the REN001 long-chain fatty acid oxidation disorders (LC-FAOD) study and provided additional development…
Needham Remains Bullish On UK-Based MedTech Stock Citing Upcoming Catalyst
LivaNova PLC (NASDAQ:LIVN) could provide an update on its RECOVER difficult-to-treat depression (DTD) trial within the next few months, representing a…
This Small Cap Cancer Company ‘Hijacks Tumors From Within,” HC Wainwright Says
HC Wainwright has initiated coverage on Genenta Science SpA (NASDAQ:GNTA) with a Buy rating and a price target of $25. “We like Genenta’s…
Regeneron’s Price Target Cut On Dim Prospects For Its Flagship Eye Product
SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc’s (NASDAQ:REGN)…